Mannheimer Swartling advises ANI Pharmaceuticals in connection with a recommended cash offer for Egetis Therapeutics

ANI Pharmaceuticals, Inc. (“ANI”) has announced a recommended cash offer to the shareholders of Egetis Therapeutics AB (publ) (“Egetis”) and to the holder of the convertible loan and the warrants issued by Egetis. The offer covers all shares, the convertible and the warrants in Egetis. ANI offers SEK 11.25 in cash per share, SEK 65,750,817 in cash for the convertible and SEK 6.99 in cash per warrant. The total value of the offer amounts to approximately SEK 5.3 billion.

ANI is a diversified biopharmaceutical company that develops, manufactures and commercializes innovative and high-quality therapeutics. The company’s business comprises rare diseases, generics and brands. The common stock of ANI is traded on The Nasdaq Global Market.

Egetis is a commercial-stage pharmaceutical company that develops and delivers innovative therapies for patients with rare diseases. The company’s lead product, EMCITATE® (tiratricol), is the first and only approved treatment for MCT8 deficiency, with marketing authorizations in the European Union and the United States. Egetis is headquartered in Stockholm, Sweden, with operations in the U.S. and Europe. The shares of Egetis are admitted to trading on Nasdaq Stockholm, Mid Cap.

ANI is advised by Mannheimer Swartling in connection with the offer. The firm’s team mainly consists of Emil Boström, Johan Berg, Gustaf Åleskog, Elina Schönbeck, Albin Wiklundh and Olga Hansen and, with respect to the financing of the offer, Daniel Khayyami, Rasmus Ringström and Paul Stone and,  with respect to FDI, Max Karlsson and Veronica Szabat.